Literature DB >> 20216419

Pharmacologic treatment of atrophic age-related macular degeneration.

Nathan L Mata1, Roger Vogel.   

Abstract

PURPOSE OF REVIEW: To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration. RECENT
FINDINGS: Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts.
SUMMARY: As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.

Entities:  

Mesh:

Year:  2010        PMID: 20216419     DOI: 10.1097/ICU.0b013e32833866c8

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  11 in total

1.  Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.

Authors:  Annal D Meleth; Pradeep Mettu; Elvira Agrón; Emily Y Chew; Srinivas R Sadda; Frederick L Ferris; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-28       Impact factor: 4.799

2.  Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.

Authors:  Wai T Wong; Samuel Dresner; Farzin Forooghian; Tanya Glaser; Lauren Doss; Mei Zhou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

3.  Novel bisretinoids of human retina are lyso alkyl ether glycerophosphoethanolamine-bearing A2PE species.

Authors:  Hye Jin Kim; Janet R Sparrow
Journal:  J Lipid Res       Date:  2018-07-09       Impact factor: 5.922

4.  Dry Age-Related Macular Degeneration Pharmacology.

Authors:  Charles B Wright; Jayakrishna Ambati
Journal:  Handb Exp Pharmacol       Date:  2017

Review 5.  [Therapy approaches for geographic atrophy].

Authors:  S Schmitz-Valckenberg; A Mössner; M Fleckenstein; P Wiedemann; F G Holz
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

6.  Alpha-phenyl-N-tert-butylnitrone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity.

Authors:  Md Nawajes A Mandal; Gennadiy P Moiseyev; Michael H Elliott; Anne Kasus-Jacobi; Xiaoman Li; Hui Chen; Lixin Zheng; Olga Nikolaeva; Robert A Floyd; Jian-Xing Ma; Robert E Anderson
Journal:  J Biol Chem       Date:  2011-07-24       Impact factor: 5.157

7.  Vitamin A-aldehyde adducts: AMD risk and targeted therapeutics.

Authors:  Janet R Sparrow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 11.205

8.  CNTF mediates neurotrophic factor secretion and fluid absorption in human retinal pigment epithelium.

Authors:  Rong Li; Rong Wen; Tina Banzon; Arvydas Maminishkis; Sheldon S Miller
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

9.  Oncostatin M protects rod and cone photoreceptors and promotes regeneration of cone outer segment in a rat model of retinal degeneration.

Authors:  Xin Xia; Yiwen Li; Deqiang Huang; Zhengying Wang; Lingyu Luo; Ying Song; Lian Zhao; Rong Wen
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

10.  Perivascular mural cells of the mouse choroid demonstrate morphological diversity that is correlated to vasoregulatory function.

Authors:  Audrey B Condren; Anil Kumar; Pradeep Mettu; Katharine J Liang; Lian Zhao; Jen-yue Tsai; Robert N Fariss; Wai T Wong
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.